• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • Login
  • 0Shopping Cart

  • COVID-19 Resources
  • Knowledge Center
  • Blog
  • Featured
    • View Webinars On-Demand
    • The In Vitro Diagnostics Market: $83 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • Free Downloads
  • About Us
  • Research Index
  • Contact
  • Search
  • Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login

NASH Drug Pipeline

  • Sort by Default
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
    NASH Drug Pipeline and Market Overview

    Published: January 6, 2020 | Price: $2,000 – $4,000

    Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate....
Knowledge Center Sidebar

Most Popular Research

  • The Worldwide Market for In Vitro Diagnostics, 13th Edition
  • Clinical Diagnostics MasterFile
  • Benchmarking for 2021: Understanding the Clinical Diagnostics Customer Experience
  • Kalorama COVID-19 Update: Impact on Molecular Diagnostics, Serology, Critical Care Tests, Vaccines and Telehealth Markets

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Point of Care Test Market is Ravaged, and Helped By Pandemic April 21, 2021
  • Watch the Companies That Make Cell and Gene Therapies For Pharma, Says New Report April 16, 2021
  • Global Biomarker Test Product Sales to Reach $63 Billion in 2027 April 14, 2021
  • Global IVD Procedures to Grow to 111.3 Billion Annually…Here’s Why April 7, 2021
  • FDA Approves Novel Cell Therapy for Multiple Myeloma March 30, 2021

Sitemap

  • Home
  • About
  • Blog
  • Contact

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Scroll to top
Register for Access Login for Access

Register for Access Login for Access

Lost your password? Register